Ligand Pharmaceuticals Inc (LGND)
73.90
+1.58
(+2.18%)
USD |
NASDAQ |
May 03, 16:00
73.90
0.00 (0.00%)
After-Hours: 20:00
Ligand Pharmaceuticals Revenue (Quarterly): 28.10M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 28.10M |
| September 30, 2023 | 32.87M |
| June 30, 2023 | 26.37M |
| March 31, 2023 | 43.98M |
| December 31, 2022 | 50.38M |
| September 30, 2022 | 59.22M |
| June 30, 2022 | 50.13M |
| March 31, 2022 | 36.52M |
| December 31, 2021 | 36.88M |
| September 30, 2021 | 64.84M |
| June 30, 2021 | 84.68M |
| March 31, 2021 | 55.15M |
| December 31, 2020 | 47.13M |
| September 30, 2020 | 41.85M |
| June 30, 2020 | 41.42M |
| March 31, 2020 | 33.16M |
| December 31, 2019 | 27.00M |
| September 30, 2019 | 24.81M |
| June 30, 2019 | 24.99M |
| March 31, 2019 | 43.48M |
| December 31, 2018 | 59.59M |
| September 30, 2018 | 45.66M |
| June 30, 2018 | 90.04M |
| March 31, 2018 | 56.16M |
| December 31, 2017 | 50.46M |
| Date | Value |
|---|---|
| September 30, 2017 | 33.38M |
| June 30, 2017 | 28.00M |
| March 31, 2017 | 29.27M |
| December 31, 2016 | 38.19M |
| September 30, 2016 | 21.62M |
| June 30, 2016 | 19.52M |
| March 31, 2016 | 29.65M |
| December 31, 2015 | 21.19M |
| September 30, 2015 | 17.70M |
| June 30, 2015 | 18.42M |
| March 31, 2015 | 14.60M |
| December 31, 2014 | 23.00M |
| September 30, 2014 | 14.97M |
| June 30, 2014 | 10.61M |
| March 31, 2014 | 15.96M |
| December 31, 2013 | 14.74M |
| September 30, 2013 | 13.00M |
| June 30, 2013 | 9.58M |
| March 31, 2013 | 11.65M |
| December 31, 2012 | 13.64M |
| September 30, 2012 | 6.375M |
| June 30, 2012 | 5.742M |
| March 31, 2012 | 5.636M |
| December 31, 2011 | 12.94M |
| September 30, 2011 | 5.741M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
24.81M
Minimum
Sep 2019
84.68M
Maximum
Jun 2021
42.60M
Average
41.42M
Median
Jun 2020
Revenue (Quarterly) Benchmarks
| ANI Pharmaceuticals Inc | 131.65M |
| ADMA Biologics Inc | 73.90M |
| Viking Therapeutics Inc | -- |
| Voyager Therapeutics Inc | 90.06M |
| Palatin Technologies Inc | 2.034M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 18.19M |
| Total Expenses (Quarterly) | 31.46M |
| EPS Diluted (Quarterly) | 1.03 |
| Enterprise Value | 1.138B |
| Gross Profit Margin (Quarterly) | 94.16% |
| Profit Margin (Quarterly) | 64.72% |
| Earnings Yield | 3.92% |
| Operating Earnings Yield | 0.75% |
| Normalized Earnings Yield | 1.248 |